Monash Partners Comprehensive Cancer Consortium

What Monash Partners Comprehensive Cancer Consortium does

Monash Partners Comprehensive Cancer Consortium (MPCCC) is a Victorian government-funded strategic alliance of eight major hospitals and Monash University that coordinates precision oncology, molecular pathology, clinical trial access, and translational cancer research across south-east Victoria. Headquartered at Monash University's Health Translation Precinct, the consortium serves a catchment of approximately 2.1 million Victorians (projected to exceed 3.5 million by 2031), with the partner network collectively caring for more than 19,000 cancer patients and delivering around 80,000 episodes of care annually. MPCCC is led by Co-Directors Prof Melissa Southey OAM and Prof Mark Shackleton, with governance drawn from the CEOs of all partner health services.

MPCCC's core products and programs are Precision Oncology, Molecular Tumour Board (MTB) meetings (fortnightly, reviewing 5–10 cases per session), Discovery and Innovation, Therapy Acceleration, Molecular Pathology, Outcomes and Impact, Research Partnerships, Training and Education, and the Australian-first Molecular Oncology and Pathology Fellows Network (eight fellows across five hospitals). The underlying technology relies on next-generation sequencing, molecular profiling, a Molecular Sequencing Registry, shared biobanking infrastructure, and a centralised MTB Portal that connects clinicians, bioinformaticians, and subject matter experts across partner organisations. The Precision Oncology Program has processed more than 1,000 patient referrals, with 20% of referred patients receiving targeted-therapy recommendations and 5% connected to clinical trials they would not otherwise access.

MPCCC is a not-for-profit consortium with no commercial product revenue, no public pricing, and no equity investors. Its primary funding stream is a 4-year Victorian Government grant administered through the Victorian Cancer Agency (current 2021–2025, renewed 2025–27), supplemented by co-contributions from partner organisations and outgoing grant programs such as the Precision Treatment Accelerator Grants ($426,184 across four projects in 2024) and Cancer Research Resource Grants ($300,000 across five projects in 2025). Customer segments are the partner health services (the operational customer base), cancer patients across Victoria (the end beneficiaries), and cancer researchers and clinicians served through training, fellowships, and the State-wide Consumer-led Research Program. Go-to-market is partnership-driven rather than commercial, supported by annual roadshows, the MPCCC Annual Cancer Forum, Precision Oncology Summits, and digital channels (website, YouTube, LinkedIn, Mailchimp newsletter).

Name

Monash Partners Comprehensive Cancer Consortium

Legal name

Monash Partners Comprehensive Cancer Consortium

Website

https://mpccc.org.au

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Monash Partners Comprehensive Cancer Consortium is a Victorian government-funded alliance of eight hospitals and Monash University that coordinates precision oncology, molecular tumour boards, clinical trial access, and translational cancer research across south-east Victoria, serving 19,000+ cancer patients annually.

Ownership category

akta.pro rank

Product category

Cancer Care Research Consortium

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

Keywords

• Precision oncology services
• Cancer research consortium
• Molecular tumour boards
• Clinical trial coordination
• Cancer care programs

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Victorian Government Funding (VCA): MPCCC is primarily funded by the Victorian Government through the Victorian Cancer Agency (VCA) and Department of Health. A 4-year funding agreement covers 2021-current, with co-contributions from partner organisations. In 2025, renewed government funding was secured for 2025–27.
2. Research Grants and Seed Funding: MPCCC distributes grants to researchers within the consortium including Cancer Research Resource (CRR) Grants ($50,000–$200,000 each), Precision Treatment Accelerator Grants (totalling $426,184 awarded to 4 projects), and Seed Funding Program for early-stage initiatives. These grants support shared research infrastructure and innovation across partner organisations.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels12 records

Core offering

MPCCC is a not-for-profit strategic alliance of eight major Victorian hospitals linked with Monash University that delivers coordinated precision oncology, molecular tumour board reviews, genomic testing pathways, clinical trial access, fellowship placements, and translational cancer research programs across south-east Victoria. It connects metropolitan, outer-metro, and regional health services to provide equitable access to cutting-edge cancer care, including molecular profiling, NGS-based diagnostics, and consumer-led research, supported primarily by Victorian Government funding through the Victorian Cancer Agency.

Product overview

MPCCC operates as a consortium platform connecting eight hospitals, Monash University, and research institutions to advance cancer care across Victoria. The core offerings include the Precision Oncology Program (flagship), Molecular Tumour Board meetings, Therapy Acceleration Program, Discovery and Innovation Program, Molecular Pathology Program, Outcomes and Impact Program, Research Partnerships, Training and Education Program, and the Molecular Oncology and Pathology Fellows Network. Additional supporting programs include Cancer Research Resource, Seed Funding Program, Precision Treatment Accelerator Grant, CRR Grant, and the Outstanding Researcher Award. The portfolio spans from genomic testing and molecular profiling to clinical trial coordination, workforce development, and consumer engagement, all coordinated through the consortium's networked model.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Oncology Program Flagship program using molecular profiling and genomic testing to identify genetic changes in cancer cells, guide treatment decisions, and facilitate participation in clinical trials for cancer patients across the partner hospital network.
• Molecular Tumour Board (MTB) Meetings Fortnightly Unified Pan-Cancer MTB meetings held across MPCCC partner organisations to discuss genomic findings, novel targeted treatments, and clinical trial matching, currently reviewing 5-10 cases per session.
• Discovery and Innovation Program Program bridging discovery research and clinical research, providing centralising infrastructure for biological materials, datasets, molecular sequencing data sharing, and seed funding for early-stage innovative projects.
• Therapy Acceleration Program Program enhancing access to cancer therapies and clinical trials for underserved communities across Victoria by leveraging technology, data sharing, and a connected clinical workforce.
• Molecular Pathology Program Program advancing molecular pathology by evaluating and strengthening referral pathways, promoting accessibility of next-generation sequencing and molecular pathology services, and fostering partnerships such as OMICO.
• Outcomes and Impact Program Program developing an evaluation framework to measure the impact of MPCCC initiatives on patient outcomes, workforce development, and equity in cancer care delivery.
• Research Partnerships Program Strategic alliance of health service and research organisations collectively caring for over 19,000 cancer patients and 80,000 episodes of care annually across Victoria.
• Training and Education Program Program supporting the next generation of leaders through PhD scholarships, Tech Talk series on cutting-edge technologies, Monash BDI-MPCCC Precision Cancer Seminars, and Fellows' workshops.
• MPCCC Molecular Oncology and Pathology Fellows Network Australian-first Fellows Program placing eight clinical oncology and pathology fellows in five leading cancer hospitals to increase access to genomic testing and connect patients with cutting-edge clinical trials.
• Consumer Leadership Program (Lead from Lived Experience) Co-designed program empowering consumers with lived experience of cancer to become leaders in shaping cancer research and care, including a six-month pilot with 20 diverse participants from across Victoria.

Quantifiable outcome

• Over 1,000 patient referrals processed through the Precision Oncology Program; 20% of referred patients receive recommendations for targeted therapies; 5% connected to clinical trials
• +5 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

22 partnerships are on record, tiered minor, core and major.

• Barwon HealthminorStrategic or Co-development Partner · 1 September 2025MPCCC announced new partnership with Barwon Health at the Cancer Forum 2025, expanding reach to deliver better cancer outcomes for more Victorians.
• Latrobe Regional HospitalminorStrategic or Co-development Partner · 1 September 2025New partnership with Latrobe Regional Hospital announced at Cancer Forum 2025. LRH is already a participating partner in MPCCC through the Gippsland Cancer Care Centre, involved in tele-trials projects for regional access to clinical trials.
• OMICO (Australian Genomic Cancer Medicine Centre)coreStrategic or Co-development Partner · 24 August 2023MPCCC and OMICO signed an MOU making MPCCC a member site in the OMICO National Clinical Trial Network (ONCTN). The partnership aims to maximise patient access to a broader range of clinical trials through coordinated distribution of trials across ONCTN member sites. Key goals include developing a systematic approach to increase Australian commercial clinical trials capacity for biomarker-dependent trials, attracting commercially sponsored trials to Australia, and increasing treatment options for molecularly screened cancer patients through clinical trials. The network spans 42 health services.
• Victorian Rare Cancer Clinical Trials Alliance (VRCCTA)coreStrategic or Co-development Partner · 1 January 2023VRCCTA, originally established by TrialHub in 2023, formally transitioned to MPCCC in 2026. VRCCTA brought together 17 health services and 21 industry partners, facilitated more than 80 patient referrals across over 40 clinical trials, and established three new rare cancer trials locally. The integration enhances MPCCC's connection between genomic testing and precision oncology.
• Victorian COVID-19 Cancer Network (VCCN)coreStrategic or Co-development Partner · 1 March 2020VCCN was established in March 2020 as a joint initiative of MPCCC and VCCC Alliance in response to challenges managing cancer care during the COVID-19 pandemic. It provides support and advice to clinicians treating cancer patients during the pandemic, advocates for patient needs, and supports the cancer workforce across the state through a digital collaboration platform with Expert Groups by tumour stream.
• Victorian Comprehensive Cancer Centre (VCCC) AlliancecoreStrategic or Co-development PartnerMPCCC engages with the VCCC Alliance on multiple collaborative initiatives including the jointly hosted Precision Oncology Summit 2023, the State-wide Consumer-led Research Program, and co-development of the Precision Oncology Roadmap. The VCCC Alliance and MPCCC also jointly developed the Victorian COVID-19 Cancer Network collaboration platform. The VCCC Alliance is a key strategic partner for statewide cancer care coordination.
• Monash Biomedicine Discovery Institute (BDI)coreStrategic or Co-development PartnerMPCCC partners with Monash BDI to host MPCCC-BDI Precision Cancer Seminars (sharing latest precision oncology research) and MPCCC-BDI Precision Cancer Workshops (providing cancer workforce training within MPCCC partner organisations). The BDI Cancer Program collaborates closely with MPCCC's Discovery and Innovation Program.
• Union for International Cancer Control (UICC)majorStrategic or Co-development PartnerMPCCC is a member of UICC, whose mission is to unite and support the cancer community to reduce the global cancer burden, promote greater equity, and ensure cancer control remains a priority in global health agendas. UICC delegates visited MPCCC in November 2025 as part of the World Cancer Leaders' Summit, learning from MPCCC's decentralised model of equitable cancer care.
• Southern Melbourne Integrated Cancer Service (SMICS)minorStrategic or Co-development PartnerSMICS is one of nine Victorian Integrated Cancer Services (VICS) that together form Victoria's cancer services improvement network. MPCCC collaborates with SMICS on cancer care improvement initiatives across southern Melbourne.
• Cancer Council VictoriaminorStrategic or Co-development PartnerCancer Council Victoria participates in the State-wide Consumer-led Research Program alongside MPCCC, VCCC Alliance, Regional Trials Network-Victoria, and the University of Melbourne. MPCCC refers patients to Cancer Council Victoria resources for cancer support services.
• Monash HealthcoreStrategic or Co-development PartnerMajor contributing partner and one of Victoria's largest public health services. The Monash Health Department of Oncology provides cancer treatment to over 1.5 million residents of southern Melbourne. Hosts MPCCC Fellows and participates in precision oncology, tele-trials, and molecular tumour board programs.
• Alfred HealthcoreStrategic or Co-development PartnerMajor contributing partner providing high-quality cancer treatment programs, translational research, and surgical and medical expertise. Home to MPCCC Co-Director Prof Mark Shackleton (Director of Oncology). Hosts Molecular Oncology and Pathology Fellows and is a key site for the Precision Oncology Program.
• Cabrini HealthcoreStrategic or Co-development PartnerMajor contributing partner and one of the largest private providers of comprehensive cancer care in Victoria. Offers rapid access to experienced specialists and the full spectrum of cancer services from early diagnosis to treatment and supportive care. Participated in the collaborative care pilot for cancer-related depression.
• Eastern HealthcoreStrategic or Co-development PartnerMajor contributing partner. The Eastern Health oncology clinic provides chemotherapy, palliative aspects of care, and diagnostic appraisal for patients referred with suspicion or prior diagnosis of malignancy. Services encompass solid tumours and haematological malignancies.
• Peninsula HealthcoreStrategic or Co-development PartnerMajor contributing partner and the only public healthcare facility on the Mornington Peninsula. Provides acute services at Frankston and Rosebud Hospitals, with dedicated haematologists and oncologists offering early cancer detection, various treatment modalities including immunotherapy, targeted therapy, endocrine therapy, and chemotherapy. Participated in collaborative care pilot.
• Monash UniversitycoreStrategic or Co-development PartnerAcademic anchor partner providing world-leading academic and research expertise to the alliance. Home to MPCCC headquarters at Monash Health Translation Precinct. Houses Biobanking Victoria initiative, Central Clinical School, and Biomedicine Discovery Institute. Provides Co-Directors (Prof Melissa Southey, Prof Mark Shackleton) and research infrastructure.
• Hudson Institute of Medical ResearchminorStrategic or Co-development PartnerParticipating partner. Scientists at the Hudson Institute undertake basic research into molecular mechanisms underlying tumour development, growth, and metastasis, as well as the relationship between the innate immune system and cancer. Discovery and development of novel cancer therapies is a key focus.
• Epworth HealthCareminorStrategic or Co-development PartnerParticipating partner offering comprehensive cancer services including specialist wards, day oncology facilities, radiation oncology, and palliative care. More than 40 Epworth accredited oncologists, surgical oncologists, and radiation oncologists practise at Epworth.
• Regional Trials Network – Victoria (RTN-V)minorStrategic or Co-development PartnerParticipates in the State-wide Consumer-led Research Program alongside MPCCC, VCCC Alliance, Cancer Council Victoria, and the University of Melbourne. RTN-V supports coordination of clinical trials across regional Victoria.
• The Kids Research Institute AustraliaminorStrategic or Co-development PartnerThe Kids Research Institute Australia (through A/Prof Raelene Endersby's Brain Tumour Research Group) collaborates with MPCCC via the BDI Cancer Program seminar series. Their research on medulloblastoma and ATR inhibitors contributes to preclinical approaches for paediatric brain cancer treatment shared through MPCCC platforms.
• Olivia Newton-John Cancer Research InstituteminorStrategic or Co-development PartnerCollaborates with MPCCC through researcher Dr Lisa Mielke (Victorian Cancer Agency Fellow and Head of the Mucosal Immunity and Cancer laboratory) who won the 2023 MPCCC Outstanding Researcher Award. Also involved in the Cancer Consumer-led Research Partnership and Head of Strategy, Impact and Equity.
• University of MelbourneminorStrategic or Co-development PartnerCollaborates through the Cancer Consumer-led Research Partnership alongside MPCCC, VCCC Alliance, RTN-V, and Cancer Council Victoria. Contributes to the Precision Oncology Roadmap submitted to Cancer Australia.

Scale indicators17 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Garvan Institute of Medical Research: Major Sydney-based medical research institute with significant programs in cancer genomics, precision oncology, and clinical translation (including the Kinghorn Centre for Clinical Genomics). Comparable in genomic/precision oncology capability but operates as a single research institute rather than a multi-hospital consortium.
• National Comprehensive Cancer Network (NCCN): US-based not-for-profit alliance of 33 leading academic cancer centres that develops clinical practice guidelines and coordinates multi-site oncology research. Analogous to MPCCC in its role as a multi-institution cancer consortium enabling translational research and shared decision frameworks.
• European Reference Networks (ERN) for Rare Cancers: EU-wide virtual networks linking healthcare providers across Europe for rare disease/cancer expertise sharing. Conceptually analogous to MPCCC's Molecular Tumour Boards and VRCCTA rare cancer trials work, applying the multi-site expert review model at continental scale.

Emerging players

• Telethon Kids Institute (Cancer Centre): Perth-based paediatric and adult research institute with oncology programs. Collaborates with MPCCC via A/Prof Raelene Endersby's Brain Tumour Research Group, and represents an emerging peer in precision paediatric cancer research.

Regional players

• Cancer Council Victoria: Victoria-focused cancer advocacy, support services, and prevention organisation. Collaborates with MPCCC on the State-wide Consumer-led Research Program and serves a comparable Victorian catchment, though its mandate is broader (prevention, advocacy) rather than precision oncology delivery.

Direct peers

• Olivia Newton-John Cancer Research Institute: Melbourne-based translational cancer research institute affiliated with Austin Health. Collaborates with MPCCC through researcher Dr Lisa Mielke (Mucosal Immunity and Cancer lab) and the Statewide Consumer-led Research Program; comparable in translational cancer research and precision oncology focus.
• OMICO (Australian Genomic Cancer Medicine Centre): National precision oncology program coordinating genomic screening and biomarker-driven clinical trial access across 42 health services (ONCTN). MPCCC joined ONCTN via MOU, making OMICO both a partner and the closest direct peer in precision oncology clinical trial infrastructure.
• NHMRC Clinical Trials Centre (CTC): Australia-wide academic clinical trials coordination centre based at the University of Sydney. Comparable peer in designing and coordinating multi-centre oncology and other clinical trials, though operates nationally rather than as a regional consortium.
• Parkville Cancer Clinical Trials Unit: Melbourne-based multi-institutional clinical trials network operating across Parkville precinct hospitals (Peter Mac, Royal Melbourne, Royal Women's, Royal Children's). A direct peer in coordinating cancer clinical trial access across a network of major hospitals in Victoria.
• Victorian Comprehensive Cancer Centre (VCCC) Alliance: Parallel Victorian cancer research consortium connecting 10 research and clinical partners. Operates overlapping programs in precision oncology, consumer-led research, and statewide cancer network initiatives, making it the most direct functional peer to MPCCC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MonashPCCC
• YouTubeyoutube.com/@monashpartnersccc
• LinkedInlinkedin.com/company/mpccc

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monash Partners Comprehensive Cancer Consortium